Focal Radiation Therapy for Prostate Cancer

This trial tests a new method for treating prostate cancer using high-dose rate brachytherapy (HDR-BT), which places radioactive material directly in or near the tumor. The aim is to control the cancer locally while minimizing side effects often associated with traditional treatments like surgery and radiation. Men recently diagnosed with prostate cancer and confirmed tumors from an MRI (a special type of scan) may be suitable candidates for this trial. The treatment plan includes receiving HDR-BT up to two times, along with regular scans and tests. As an unphased trial, this study provides patients the opportunity to explore innovative treatment options that might not be available elsewhere.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

A previous study found high-dose rate brachytherapy (HDR-BT) to be a safe and manageable treatment for prostate cancer. This method places radioactive material directly in or near the tumor. Research has shown that HDR-BT effectively controls cancer while maintaining low side effects. One study found that even patients with prior radiation treatment handled HDR-BT well. Another study reported very few severe side effects, even after many years. Overall, HDR-BT has a strong safety record for treating prostate cancer.¹²³⁴⁵

High-Dose Rate Brachytherapy (HDR-BT) is unique because it delivers a concentrated dose of radiation directly to the dominant prostate lesion, reducing exposure to surrounding healthy tissues. Unlike traditional external beam radiation, which can take several weeks, HDR-BT is completed in just one or two sessions, spaced a few weeks apart. Researchers are excited about this treatment because it has the potential to minimize side effects while effectively targeting cancer cells, offering a promising alternative to more invasive prostate cancer treatments.

Research has shown that high-dose rate brachytherapy (HDR-BT), the treatment under study in this trial, effectively treats prostate cancer. HDR-BT controls cancer by placing radiation directly inside or near the tumor. One study found that over 90% of patients with intermediate-risk prostate cancer remained disease-free after HDR-BT. Another report highlighted that HDR-BT provides strong disease control for men with localized prostate cancer. Overall, HDR-BT is a promising treatment option that may reduce side effects compared to traditional methods.⁶⁷⁸⁹¹⁰